Cargando…
PReS-FINAL-2093: Can clinical response within 12 weeks in JIA-etanercept receivers predict the future clinical remission?
Autores principales: | Pratsidou-Gertsi, P, Verykouki, E, Pardalos, G, Trachana, M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4044539/ http://dx.doi.org/10.1186/1546-0096-11-S2-P105 |
Ejemplares similares
-
The use of Etanercept and Adalimumab in the management of JIA: a 5-year follow-up study
por: Trachana, M, et al.
Publicado: (2008) -
Impact of a 2-yr anti-TNF treatment on the quality of life in JIA patients: a parent's/patient’s view
por: Diafa, K, et al.
Publicado: (2011) -
The role of synovial fluid cytokines IL-6, IL-23 and IL-17 in the pathogenesis and persistence of synovial inflammation in JIA patients
por: Tzimouli, V, et al.
Publicado: (2008) -
PReS-FINAL-2142: Predictors of persistent remission following etanercept (ETN) withdrawal in patients with juvenile idiopathic arthritis (JIA)
por: Perfetti, F, et al.
Publicado: (2013) -
The impact of a 2-year Etanercept administration on growth of patients with juvenile idiopathic arthritis
por: Trachana, M, et al.
Publicado: (2011)